While Adaptive Biotechnologies Corp has underperformed by -6.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADPT rose by 166.32%, with highs and lows ranging from $9.01 to $2.28, whereas the simple moving average jumped by 35.92% in the last 200 days.
On March 21, 2025, Goldman Upgraded Adaptive Biotechnologies Corp (NASDAQ: ADPT) to Buy. Scotiabank also rated ADPT shares as ‘Sector Outperform’, setting a target price of $15 on the company’s shares in an initiating report dated January 05, 2023. Piper Sandler December 21, 2022d the rating to Overweight on December 21, 2022, and set its price target from $7.50 to $14. Credit Suisse initiated its ‘Underperform’ rating for ADPT, as published in its report on August 25, 2022. Piper Sandler’s report from June 03, 2022 suggests a price prediction of $7.50 for ADPT shares, giving the stock a ‘Neutral’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of Adaptive Biotechnologies Corp (ADPT)
Further, the quarter-over-quarter increase in sales is 3.66%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Adaptive Biotechnologies Corp’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -62.41% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.81, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and ADPT is recording an average volume of 1.76M. On a monthly basis, the volatility of the stock is set at 9.60%, whereas on a weekly basis, it is put at 6.53%, with a loss of -8.69% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.71, showing growth from the present price of $7.67, which can serve as yet another indication of whether ADPT is worth investing in or should be passed over.
How Do You Analyze Adaptive Biotechnologies Corp Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.61%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.54% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ADPT shares are owned by institutional investors to the tune of 92.54% at present.
